Cargando…

Antitumor effects of bevacizumab in combination with fluoropyrimidine drugs on human oral squamous cell carcinoma

Vascular endothelial growth factor (VEGF) serves an important role in new blood vessel formation or angiogenesis, which is a critical event in tumor growth and metastasis. Bevacizumab is a humanized monoclonal antibody against VEGF-A, whereas S-1 is a fluoropyrimidine antineoplastic agent that induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Itashiki, Yasutaka, Harada, Koji, Takenawa, Takanori, Ferdous, Tarannum, Ueyama, Yoshiya, Mishima, Katsuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371954/ https://www.ncbi.nlm.nih.gov/pubmed/34429770 http://dx.doi.org/10.3892/ol.2021.12991

Ejemplares similares

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo
por: Harada, Koji, et al.
Publicado: (2017)

Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer()
por: Harada, Koji, et al.
Publicado: (2017)

Osteogenic cell fractions isolated from mouse tongue muscle
por: HARADA, KOJI, et al.
Publicado: (2015)

Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma
por: Yamanouchi, Ryota, et al.
Publicado: (2018)

Prognostic significance of FOXM1 in oral squamous cell carcinoma patients treated by docetaxel-containing regimens
por: Harada, Koji, et al.
Publicado: (2019)

Elemental Diet Accelerates the Recovery From Oral Mucositis and Dermatitis Induced by 5-Fluorouracil Through the Induction of Fibroblast Growth Factor 2
por: Harada, Koji, et al.
Publicado: (2017)

PD-L1 expression in malignant salivary gland tumors
por: Harada, Koji, et al.
Publicado: (2018)

An elemental diet protects mouse salivary glands from 5-fluorouracil-induced atrophy
por: Harada, Koji, et al.
Publicado: (2022)

Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors
por: Harada, Koji, et al.
Publicado: (2016)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

In vivo Antitumor Effects of Fluoropyrimidines on Colon Adenocarcinoma 38 and Enhancement by Leucovorin
por: Iigo, Masaaki, et al.
Publicado: (1992)

Nonlinear Dynamic Analysis of Vowels in Cleft Palate Children with or without Hypernasality
por: Mishima, Katsuaki, et al.
Publicado: (2012)

Quantitative Analysis of Velopharyngeal Movement by Applying Principal Component Analysis to Range Images Produced by a Three-Dimensional Endoscope
por: Nakano, Asuka, et al.
Publicado: (2017)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation
por: Milano, G, et al.
Publicado: (2004)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol
por: Avallone, Antonio, et al.
Publicado: (2020)

Combined adjuvants of poly(I:C) plus LAG‐3‐Ig improve antitumor effects of tumor‐specific T cells, preventing their exhaustion
por: Kano, Yosuke, et al.
Publicado: (2016)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tian, Wei, et al.
Publicado: (2023)

Association of Preoperative Radiation Effect with Tumor Angiogenesis and Vascular Endothelial Growth Factor in Oral Squamous Cell Carcinoma
por: Shintani, Satoru, et al.
Publicado: (2000)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
por: Katsumata, N., et al.
Publicado: (2011)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
por: Jung, Hyun Ae, et al.
Publicado: (2013)

Biomarkers for antitumor activity of bevacizumab in gastric cancer models
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2012)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
por: Iwai, Toshiki, et al.
Publicado: (2016)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma
por: Yamanaka, T, et al.
Publicado: (2007)

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
por: Lam, Ka-On, et al.
Publicado: (2019)

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Kataria, Satya Pal, et al.
Publicado: (2022)

Anti-EpCAM monoclonal antibody exerts antitumor activity against oral squamous cell carcinomas
por: Kaneko, Mika K., et al.
Publicado: (2020)

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer
por: Tabernero, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vrss740p3t27ivvmu1b36k0o3j